Filamentous temperature sensitive mutant Z: a putative target to combat antibacterial resistance

Sumaiya Kifayat1, Vidyasrilekha Yele2, Akram Ashames3,4

  • 1Department of Pharmacology, NIMS Institute of Pharmacy, NIMS University Rajasthan Jaipur 303121 India kifayatsumaiya@gmail.com bharathsanapalli@yahoo.in +91-9291661992.

RSC Advances
|April 14, 2023
PubMed

Insights

Antibacterial resistance (ABR) is a growing global threat. This review explores Filamentous Temperature Sensitive mutant Z (FtsZ) as a novel target for new antibacterial drugs, examining inhibitors and detection methods.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Structural Biology

Background:

  • The rise of antibacterial resistance (ABR) poses a significant global health challenge, necessitating novel therapeutic strategies.
  • The discovery of antibiotics revolutionized medicine, but widespread resistance has emerged due to various factors including overuse and bacterial adaptation.
  • Filamentous Temperature Sensitive mutant Z (FtsZ), a bacterial tubulin homolog crucial for cell division and lacking mammalian counterparts, represents a promising antibacterial target.

Purpose of the Study:

  • To review the structural characteristics of FtsZ and its role in bacterial cell division.
  • To summarize existing natural, semi-synthetic, peptide, and synthetic FtsZ inhibitors.
  • To discuss in vitro methods for detecting FtsZ-drug interactions and evaluating drug efficacy.

Main Methods:

  • Literature review of FtsZ crystal structures and identified inhibitors.
  • Analysis of reported inhibitory activities of various FtsZ-targeting compounds.
  • Compilation of in vitro assays for FtsZ-drug complex quantification and polymerization inhibition.

Main Results:

  • Over 2176 FtsZ crystal structures have been determined, facilitating structure-based drug design.
  • Numerous FtsZ inhibitors from diverse chemical classes have been identified, demonstrating varying potencies.
  • Established in vitro methods exist for characterizing FtsZ inhibitors and their mechanisms.

Conclusions:

  • FtsZ is a validated and attractive target for developing novel antibacterials to combat resistance.
  • Further research into FtsZ inhibitors and their mechanisms is crucial for addressing the ABR crisis.
  • Standardized in vitro assays are essential for the efficient discovery and development of new antibacterial agents targeting FtsZ.